Eintrag weiter verarbeiten
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , , , , , |
| In: | Blood, 118, 2011, 8, S. 2077-2084 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Schrappe, Martin Valsecchi, Maria Grazia Bartram, Claus R. Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Parasole, Rosanna Zimmermann, Martin Dworzak, Michael Buldini, Barbara Reiter, Alfred Basso, Giuseppe Klingebiel, Thomas Messina, Chiara Ratei, Richard Cazzaniga, Giovanni Koehler, Rolf Locatelli, Franco Schäfer, Beat W. Aricò, Maurizio Welte, Karl van Dongen, Jacques J.M. Gadner, Helmut Biondi, Andrea Conter, Valentino Schrappe, Martin Valsecchi, Maria Grazia Bartram, Claus R. Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Parasole, Rosanna Zimmermann, Martin Dworzak, Michael Buldini, Barbara Reiter, Alfred Basso, Giuseppe Klingebiel, Thomas Messina, Chiara Ratei, Richard Cazzaniga, Giovanni Koehler, Rolf Locatelli, Franco Schäfer, Beat W. Aricò, Maurizio Welte, Karl van Dongen, Jacques J.M. Gadner, Helmut Biondi, Andrea Conter, Valentino |
|---|---|
| author |
Schrappe, Martin Valsecchi, Maria Grazia Bartram, Claus R. Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Parasole, Rosanna Zimmermann, Martin Dworzak, Michael Buldini, Barbara Reiter, Alfred Basso, Giuseppe Klingebiel, Thomas Messina, Chiara Ratei, Richard Cazzaniga, Giovanni Koehler, Rolf Locatelli, Franco Schäfer, Beat W. Aricò, Maurizio Welte, Karl van Dongen, Jacques J.M. Gadner, Helmut Biondi, Andrea Conter, Valentino |
| spellingShingle |
Schrappe, Martin Valsecchi, Maria Grazia Bartram, Claus R. Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Parasole, Rosanna Zimmermann, Martin Dworzak, Michael Buldini, Barbara Reiter, Alfred Basso, Giuseppe Klingebiel, Thomas Messina, Chiara Ratei, Richard Cazzaniga, Giovanni Koehler, Rolf Locatelli, Franco Schäfer, Beat W. Aricò, Maurizio Welte, Karl van Dongen, Jacques J.M. Gadner, Helmut Biondi, Andrea Conter, Valentino Blood Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study Cell Biology Hematology Immunology Biochemistry |
| author_sort |
schrappe, martin |
| spelling |
Schrappe, Martin Valsecchi, Maria Grazia Bartram, Claus R. Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Parasole, Rosanna Zimmermann, Martin Dworzak, Michael Buldini, Barbara Reiter, Alfred Basso, Giuseppe Klingebiel, Thomas Messina, Chiara Ratei, Richard Cazzaniga, Giovanni Koehler, Rolf Locatelli, Franco Schäfer, Beat W. Aricò, Maurizio Welte, Karl van Dongen, Jacques J.M. Gadner, Helmut Biondi, Andrea Conter, Valentino 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2011-03-338707 <jats:title>Abstract</jats:title> <jats:p>The prognostic value of MRD in large series of childhood T-ALL has not yet been established. Trial AIEOP-BFM-ALL 2000 introduced standardized quantitative assessment of MRD for stratification, based on immunoglobulin and TCR gene rearrangements as polymerase chain reaction targets: Patients were considered MRD standard risk (MRD-SR) if MRD was negative at day 33 (time point 1 [TP1]) and day 78 (TP2), analyzed by at least 2 sensitive markers; MRD intermediate risk (MRD-IR) if positive either at day 33 or 78 and < 10−3 at day 78; and MRD high risk (MRD-HR) if ≥ 10−3 at day 78. A total of 464 patients with T-ALL were stratified by MRD: 16% of them were MRD-SR, 63% MRD-IR, and 21% MRD-HR. Their 7-year event-free-survival (SE) was 91.1% (3.5%), 80.6% (2.3%), and 49.8% (5.1%) (P < .001), respectively. Negativity of MRD at TP1 was the most favorable prognostic factor. An excellent outcome was also obtained in 32% of patients turning MRD negative only at TP2, indicating that early (TP1) MRD levels were irrelevant if MRD at TP2 was negative (48% of all patients). MRD ≥ 10−3 at TP2 constitutes the most important predictive factor for relapse in childhood T-ALL. The study is registered at http://www.clinicaltrials.gov; “Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia,” protocol identification #NCT00430118 for BFM and #NCT00613457 for AIEOP.</jats:p> Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study Blood |
| doi_str_mv |
10.1182/blood-2011-03-338707 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDExLTAzLTMzODcwNw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDExLTAzLTMzODcwNw |
| institution |
DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 |
| imprint |
American Society of Hematology, 2011 |
| imprint_str_mv |
American Society of Hematology, 2011 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
schrappe2011latemrdresponsedeterminesrelapseriskoverallandinsubsetsofchildhoodtcellallresultsoftheaieopbfmall2000study |
| publishDateSort |
2011 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_unstemmed |
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_full |
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_fullStr |
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_full_unstemmed |
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_short |
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_sort |
late mrd response determines relapse risk overall and in subsets of childhood t-cell all: results of the aieop-bfm-all 2000 study |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2011-03-338707 |
| publishDate |
2011 |
| physical |
2077-2084 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>The prognostic value of MRD in large series of childhood T-ALL has not yet been established. Trial AIEOP-BFM-ALL 2000 introduced standardized quantitative assessment of MRD for stratification, based on immunoglobulin and TCR gene rearrangements as polymerase chain reaction targets: Patients were considered MRD standard risk (MRD-SR) if MRD was negative at day 33 (time point 1 [TP1]) and day 78 (TP2), analyzed by at least 2 sensitive markers; MRD intermediate risk (MRD-IR) if positive either at day 33 or 78 and < 10−3 at day 78; and MRD high risk (MRD-HR) if ≥ 10−3 at day 78. A total of 464 patients with T-ALL were stratified by MRD: 16% of them were MRD-SR, 63% MRD-IR, and 21% MRD-HR. Their 7-year event-free-survival (SE) was 91.1% (3.5%), 80.6% (2.3%), and 49.8% (5.1%) (P < .001), respectively. Negativity of MRD at TP1 was the most favorable prognostic factor. An excellent outcome was also obtained in 32% of patients turning MRD negative only at TP2, indicating that early (TP1) MRD levels were irrelevant if MRD at TP2 was negative (48% of all patients). MRD ≥ 10−3 at TP2 constitutes the most important predictive factor for relapse in childhood T-ALL. The study is registered at http://www.clinicaltrials.gov; “Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia,” protocol identification #NCT00430118 for BFM and #NCT00613457 for AIEOP.</jats:p> |
| container_issue |
8 |
| container_start_page |
2077 |
| container_title |
Blood |
| container_volume |
118 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347781112791048 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:00:40.767Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Late+MRD+response+determines+relapse+risk+overall+and+in+subsets+of+childhood+T-cell+ALL%3A+results+of+the+AIEOP-BFM-ALL+2000+study&rft.date=2011-08-25&genre=article&issn=1528-0020&volume=118&issue=8&spage=2077&epage=2084&pages=2077-2084&jtitle=Blood&atitle=Late+MRD+response+determines+relapse+risk+overall+and+in+subsets+of+childhood+T-cell+ALL%3A+results+of+the+AIEOP-BFM-ALL+2000+study&aulast=Conter&aufirst=Valentino&rft_id=info%3Adoi%2F10.1182%2Fblood-2011-03-338707&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347781112791048 |
| author | Schrappe, Martin, Valsecchi, Maria Grazia, Bartram, Claus R., Schrauder, André, Panzer-Grümayer, Renate, Möricke, Anja, Parasole, Rosanna, Zimmermann, Martin, Dworzak, Michael, Buldini, Barbara, Reiter, Alfred, Basso, Giuseppe, Klingebiel, Thomas, Messina, Chiara, Ratei, Richard, Cazzaniga, Giovanni, Koehler, Rolf, Locatelli, Franco, Schäfer, Beat W., Aricò, Maurizio, Welte, Karl, van Dongen, Jacques J.M., Gadner, Helmut, Biondi, Andrea, Conter, Valentino |
| author_facet | Schrappe, Martin, Valsecchi, Maria Grazia, Bartram, Claus R., Schrauder, André, Panzer-Grümayer, Renate, Möricke, Anja, Parasole, Rosanna, Zimmermann, Martin, Dworzak, Michael, Buldini, Barbara, Reiter, Alfred, Basso, Giuseppe, Klingebiel, Thomas, Messina, Chiara, Ratei, Richard, Cazzaniga, Giovanni, Koehler, Rolf, Locatelli, Franco, Schäfer, Beat W., Aricò, Maurizio, Welte, Karl, van Dongen, Jacques J.M., Gadner, Helmut, Biondi, Andrea, Conter, Valentino, Schrappe, Martin, Valsecchi, Maria Grazia, Bartram, Claus R., Schrauder, André, Panzer-Grümayer, Renate, Möricke, Anja, Parasole, Rosanna, Zimmermann, Martin, Dworzak, Michael, Buldini, Barbara, Reiter, Alfred, Basso, Giuseppe, Klingebiel, Thomas, Messina, Chiara, Ratei, Richard, Cazzaniga, Giovanni, Koehler, Rolf, Locatelli, Franco, Schäfer, Beat W., Aricò, Maurizio, Welte, Karl, van Dongen, Jacques J.M., Gadner, Helmut, Biondi, Andrea, Conter, Valentino |
| author_sort | schrappe, martin |
| container_issue | 8 |
| container_start_page | 2077 |
| container_title | Blood |
| container_volume | 118 |
| description | <jats:title>Abstract</jats:title> <jats:p>The prognostic value of MRD in large series of childhood T-ALL has not yet been established. Trial AIEOP-BFM-ALL 2000 introduced standardized quantitative assessment of MRD for stratification, based on immunoglobulin and TCR gene rearrangements as polymerase chain reaction targets: Patients were considered MRD standard risk (MRD-SR) if MRD was negative at day 33 (time point 1 [TP1]) and day 78 (TP2), analyzed by at least 2 sensitive markers; MRD intermediate risk (MRD-IR) if positive either at day 33 or 78 and < 10−3 at day 78; and MRD high risk (MRD-HR) if ≥ 10−3 at day 78. A total of 464 patients with T-ALL were stratified by MRD: 16% of them were MRD-SR, 63% MRD-IR, and 21% MRD-HR. Their 7-year event-free-survival (SE) was 91.1% (3.5%), 80.6% (2.3%), and 49.8% (5.1%) (P < .001), respectively. Negativity of MRD at TP1 was the most favorable prognostic factor. An excellent outcome was also obtained in 32% of patients turning MRD negative only at TP2, indicating that early (TP1) MRD levels were irrelevant if MRD at TP2 was negative (48% of all patients). MRD ≥ 10−3 at TP2 constitutes the most important predictive factor for relapse in childhood T-ALL. The study is registered at http://www.clinicaltrials.gov; “Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia,” protocol identification #NCT00430118 for BFM and #NCT00613457 for AIEOP.</jats:p> |
| doi_str_mv | 10.1182/blood-2011-03-338707 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDExLTAzLTMzODcwNw |
| imprint | American Society of Hematology, 2011 |
| imprint_str_mv | American Society of Hematology, 2011 |
| institution | DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T18:00:40.767Z |
| match_str | schrappe2011latemrdresponsedeterminesrelapseriskoverallandinsubsetsofchildhoodtcellallresultsoftheaieopbfmall2000study |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 2077-2084 |
| publishDate | 2011 |
| publishDateSort | 2011 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Schrappe, Martin Valsecchi, Maria Grazia Bartram, Claus R. Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Parasole, Rosanna Zimmermann, Martin Dworzak, Michael Buldini, Barbara Reiter, Alfred Basso, Giuseppe Klingebiel, Thomas Messina, Chiara Ratei, Richard Cazzaniga, Giovanni Koehler, Rolf Locatelli, Franco Schäfer, Beat W. Aricò, Maurizio Welte, Karl van Dongen, Jacques J.M. Gadner, Helmut Biondi, Andrea Conter, Valentino 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2011-03-338707 <jats:title>Abstract</jats:title> <jats:p>The prognostic value of MRD in large series of childhood T-ALL has not yet been established. Trial AIEOP-BFM-ALL 2000 introduced standardized quantitative assessment of MRD for stratification, based on immunoglobulin and TCR gene rearrangements as polymerase chain reaction targets: Patients were considered MRD standard risk (MRD-SR) if MRD was negative at day 33 (time point 1 [TP1]) and day 78 (TP2), analyzed by at least 2 sensitive markers; MRD intermediate risk (MRD-IR) if positive either at day 33 or 78 and < 10−3 at day 78; and MRD high risk (MRD-HR) if ≥ 10−3 at day 78. A total of 464 patients with T-ALL were stratified by MRD: 16% of them were MRD-SR, 63% MRD-IR, and 21% MRD-HR. Their 7-year event-free-survival (SE) was 91.1% (3.5%), 80.6% (2.3%), and 49.8% (5.1%) (P < .001), respectively. Negativity of MRD at TP1 was the most favorable prognostic factor. An excellent outcome was also obtained in 32% of patients turning MRD negative only at TP2, indicating that early (TP1) MRD levels were irrelevant if MRD at TP2 was negative (48% of all patients). MRD ≥ 10−3 at TP2 constitutes the most important predictive factor for relapse in childhood T-ALL. The study is registered at http://www.clinicaltrials.gov; “Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia,” protocol identification #NCT00430118 for BFM and #NCT00613457 for AIEOP.</jats:p> Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study Blood |
| spellingShingle | Schrappe, Martin, Valsecchi, Maria Grazia, Bartram, Claus R., Schrauder, André, Panzer-Grümayer, Renate, Möricke, Anja, Parasole, Rosanna, Zimmermann, Martin, Dworzak, Michael, Buldini, Barbara, Reiter, Alfred, Basso, Giuseppe, Klingebiel, Thomas, Messina, Chiara, Ratei, Richard, Cazzaniga, Giovanni, Koehler, Rolf, Locatelli, Franco, Schäfer, Beat W., Aricò, Maurizio, Welte, Karl, van Dongen, Jacques J.M., Gadner, Helmut, Biondi, Andrea, Conter, Valentino, Blood, Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_full | Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_fullStr | Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_full_unstemmed | Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_short | Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| title_sort | late mrd response determines relapse risk overall and in subsets of childhood t-cell all: results of the aieop-bfm-all 2000 study |
| title_unstemmed | Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2011-03-338707 |